With Millipore® CTDMO Services we support small molecule API synthesis projects from milligram to commercial quantities. We are the partner to address the most difficult challenges, whether the target is difficult to handle, synthesize, or source. With a true consultative and partnered approach, our services reduce complexity and minimize program risk in a cost-effective manner.
Clients can speed up drug development by partnering with us on any of the following types of programs: HPAPIs, APIs, Novel Format Conjugates, Linker-Payloads, PEGs, or Targeted Protein Degradation.Talk To an Expert
From conceptualization to the first GMP batch, our project teams work in close collaboration with our client’s scientists to ensure their vision becomes a reality.
Our quality and regulatory experts are available to provide guidance on a phase appropriate and efficient approach throughout the various clinical stages.
As a program approaches commercialization, we offer consultation and implementation of new technologies and efficiencies to ensure the drug is competitive in the marketplace upon approval.
With decades of experience across a variety of chemistries and therapeutic indications, we are the team for custom API synthesis. From early development to commercial supply, our global network of development and manufacturing facilities is ready to support our clients’ programs. With Millipore® CTDMO Services we offer:
With over 30 years of experience in the production of highly potent active pharmaceutical ingredients (HPAPIs), we are an industry leader with the expertise needed to tackle the unique handling challenges of these therapeutic compounds. With Millipore® CTDMO Services we offer:
With decades of expertise in activated and functionalized PEGs, we offer the technical, quality, and regulatory support needed to maximize product efficiency through optimized release kinetics and targeted drug delivery. With Millipore® CTDMO Services we offer:
As industry experts in development and production of linker-payloads and PEGs as well as ADC bioconjugation, we also offer comprehensive support for novel format conjugate programs. With Millipore® CTDMO Services we offer:
As our clients prepare for entry into the clinic, we are here to support in the pursuit of drugging the “undruggable” targets. With a true consultative partnership approach, our experts have the flexibility to provide these unique materials regardless of clinical phase. With Millipore® CTDMO Services we offer:
With over 20 years of experience in linker-payload technology, we have a long history with this modality, partnering with most early ADC linker-payload pioneers. Our small molecule development scientists partner with clients to provide technical expertise needed to develop synthetic routes for the most challenging of molecules. With Millipore® CTDMO Services we offer:
Accelerate drug development efforts with our comprehensive product line of payloads and advanced payload intermediates. These products add value to our clients’ program by reducing development costs, decreasing supply chain complexity, and increasing speed of synthesis through reduction of required reaction steps – together accelerating speed to clinic. With Millipore® CTDMO Services we offer:
We are a single organization with a global network to deliver CDMO services across all stages of the molecule value chain.
Commercialization for large scale API production and portfolio lipids. Continued investment to expand our global network of API production facilities offers immediate development and manufacturing capacity..
Development, manufacturing and launch site for lipids, functionalized polyethylene glycols (PEGs), and APIs.
Our API and HPAPI manufacturing sites are SafeBridge certified. Continued investment and expansion in these facilities build upon our decades of high potency expertise and makes us one of the largest single-digit nanogram OEL CTDMO providers in the world.Learn More
Our ADC & Bioconjugation Center of Excellence offers ADC and Bioconjugation capabilities from pre-clinical development to commercial manufacturing.Learn More
In this white paper, we explore monodisperse polyethylene glycols help overcome hydrophobicity challenges.
To continue reading please sign in or create an account.Don't Have An Account?